Literature DB >> 2851853

Guillain-Barré syndrome associated with cytomegalovirus infection.

I K Hart1, P G Kennedy.   

Abstract

Three cases of Guillain-Barré syndrome associated with serological evidence of active cytomegalovirus (CMV) infection are described. There are a variety of problems in establishing a causal role for cytomegalovirus in the development of the Guillain-Barré syndrome, the most important of which relates to the unequivocal demonstration of a primary infection preceding the condition. It is postulated that an immune-mediated mechanism probably plays an important role in pathogenesis whether it is associated with cytomegalovirus or other human herpesviruses.

Entities:  

Mesh:

Year:  1988        PMID: 2851853

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  7 in total

Review 1.  Human cytomegalovirus infection.

Authors:  J G Sissons; L K Borysiewicz
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

2.  Weakness in pregnancy - expect the unexpected.

Authors:  S Furara; M Maw; F Khan; K Powell
Journal:  Obstet Med       Date:  2008-12-01

3.  Fisher's syndrome associated with chickenpox and anti-GQ1b antibody.

Authors:  H Takano; N Yuki
Journal:  J Neurol       Date:  1995-03       Impact factor: 4.849

4.  Adoptively transferred anti-idiotype pulsed B cells mediate autoimmune myocarditis.

Authors:  R E Paque; R Miller
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

5.  Autoanti-idiotypes exhibit mimicry of myocyte antigens in virus-induced myocarditis.

Authors:  R E Paque; R Miller
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Effect of acute cytomegalovirus infection on drug-induced SLE.

Authors:  A Schattner; Z Sthoeger; D Geltner
Journal:  Postgrad Med J       Date:  1994-10       Impact factor: 2.401

Review 7.  SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms.

Authors:  Shahrzad Shoraka; Maria Lucia Brito Ferreira; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.